In its Oct. 30 filing with the U.S. Securities and Exchange Commission, PGDx said the final amount of the round, expected to close in the coming weeks, could be higher or lower than the $111.5 million target.
Cancer diagnostics firm bio Genome Diagnostics ( PGDx ) has raised $ 65 million in an open equity financing round . It aims to raise a total of $ 200 m in the round . PGDx offers cancer patients clinical analysis to provide better diagnosis and treatments . Thus far , 12 investors have purchased equity . PGDx already gained $ 21.4 m in a round A funding round in 2015 , adding to its previous $ 2.8 m in seed funding .